Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CD38 | P28907 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600893 | 0.77 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL7498616 | 0.75 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL1816568 | 0.74 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL7494482 | 0.72 | CYP3A4 (0.65) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL4988071 | 0.72 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6358458 | 0.72 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL7496961 | 0.71 | SMN1; SMN2 (0.61) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5925957 | 0.71 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL6215004 | 0.70 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL7493636 | 0.70 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280944-A1 | Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280944-A1 | Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux | GIPR, GRPR, HRH2 | CYP3A4 255/4885CYP2C9 1059/4885CYP2D6 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.